Related Experiment Video
Updated: May 19, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
[High-dose tirofiban in patients with acute ST-segment elevation myocardial infarction undergoing primary
Li-hui Ren1, Jian-jun Peng, Hui-ming Ye
1Department of Cardiology, Beijing Shijitan Hospital, Beijing, China.
Insights
High-dose tirofiban significantly improved ST-segment resolution and left ventricular ejection fraction in ST-elevation myocardial infarction patients undergoing primary PCI, without increasing hemorrhage risk.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- ST-elevation myocardial infarction (STEMI) is a critical condition requiring rapid reperfusion.
- Primary percutaneous coronary intervention (PCI) is the standard treatment for STEMI.
- Platelet aggregation inhibition is crucial during primary PCI.
Purpose of the Study:
- To assess the clinical outcomes of high-dose tirofiban therapy.
- To compare high-dose tirofiban with standard-dose tirofiban in STEMI patients undergoing primary PCI.
Main Methods:
- A randomized trial involving 104 STEMI patients undergoing primary PCI.
- Patients were assigned to either high-dose or normal-dose tirofiban groups.
- Evaluated ECG ST-segment resolution and left ventricular ejection fraction (LVEF) at 90 days post-PCI.
Main Results:
- High-dose tirofiban group showed significantly improved ST-segment resolution post-PCI (38% ± 12% vs 34% ± 13%, P < 0.05).
- LVEF significantly improved in the high-dose group by day 90 (60.1% ± 1.1% vs 56.0% ± 1.2%, P < 0.05).
- No significant difference in major or moderate hemorrhage rates between groups.
Conclusions:
- High-dose tirofiban enhances myocardial reperfusion and clinical outcomes in STEMI patients undergoing primary PCI.
- Supports the benefit of intensified platelet inhibition in this patient population.
Objective:
To evaluate the clinical outcomes of high-dose tirofiban in patients with ST-elevation myocardial infarction (ASTEMI) undergoing primary percutaneous coronary intervention (PCI).
Methods:
A total of 104 consecutive ASTEMI patients undergoing primary PCI were enrolled from January 2010 to February 2011. They were randomized into the high-dose tirofiban group (n = 52) and the normal-dose tirofiban group (n = 52). We measured the sumST-segment resolution of ECG post-PCI respectively and left ventricular ejective fraction (LVEF) at Day 90 post-PCI.
Results:
After PCI, the sumST-segment resolution of ECG of the high-dose tirofiban group significantly improved than that of the normal-dose tirofiban group (38% ± 12% vs 34% ± 13%, P < 0.05). Before PCI, LVEF of two groups is 50.2% ± 1.4% vs 49.6% ± 1.1% (P > 0.05), but at day 90 post-PCI, LVEF had significant difference between two groups (60.1% ± 1.1% vs 56.0% ± 1.2%, P < 0.05). The rates of major and moderate hemorrhage did not differ significantly between two groups.
Conclusion:
High-dose tirofiban improves myocardial reperfusion and clinical outcome. It re-emphasizes the importance of further platelet aggregation inhibition in ASTEMI patients undergoing primary PCI.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Acute Coronary Syndrome V: Nursing Management